Yakira Capital Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Yakira Capital Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-14,200	Closed	-$20K	–	124
2017 Q3	$20K	Hold	14,200	–	–	0.01%	112
2017 Q2	$21K	Hold	14,200	–	–	0.01%	103
2017 Q1	$36K	Hold	14,200	–	–	0.01%	98
2016 Q4	$36K	Hold	14,200	–	–	0.02%	79
2016 Q3	$44K	Hold	14,200	–	–	0.01%	74
2016 Q2	$46K	Hold	14,200	–	–	0.02%	95
2016 Q1	$44K	Hold	14,200	–	–	0.01%	104
2015 Q4	$57K	Hold	14,200	–	–	0.01%	109
2015 Q3	$65K	Hold	14,200	–	–	0.04%	112
2015 Q2	$74K	Hold	14,200	–	–	0.04%	111
2015 Q1	$89K	Hold	14,200	–	–	0.06%	80
2014 Q4	$89K	Hold	14,200	–	–	0.07%	86
2014 Q3	$86K	Hold	14,200	–	–	0.06%	86
2014 Q2	$94K	Buy	+14,200	New	+$160K	0.07%	97
2014 Q1	–	Sell	-3,985	Closed	-$43K	–	104
2013 Q4	$43K	Buy	+3,985	New	+$44K	0.04%	91

Other funds holding ECYT

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Yakira Capital Management's ECYT Position: Q4 2017 in Review

Yakira Capital Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2017, closing a stake of 14,200 shares — an estimated $20K sold.

Yakira Capital Management first reported a position in ECYT in Q4 2013 and held it in 15 quarters. The position peaked at $94K in Q2 2014. 71 funds tracked by Wall St. Rank hold ECYT as of Q4 2017.

Yakira Capital Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
Yakira Capital Management sold 14,200 Endocyte, Inc. Common Stock shares in Q4 2017, an estimated $20K.
Yakira Capital Management first reported a position in Endocyte, Inc. Common Stock in Q4 2013 and held it in 15 quarters.
Yakira Capital Management's Endocyte, Inc. Common Stock position peaked at $94K in Q2 2014.
71 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2017.

Based on Yakira Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.